These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17495632)

  • 21. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.
    Whitton PS
    Curr Opin Investig Drugs; 2010 Jul; 11(7):788-94. PubMed ID: 20571974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions.
    McGeer PL; McGeer EG
    Alzheimer Dis Assoc Disord; 1998; 12 Suppl 2():S1-6. PubMed ID: 9769023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation.
    Teismann P; Schulz JB
    Cell Tissue Res; 2004 Oct; 318(1):149-61. PubMed ID: 15338271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases.
    Takenouchi T; Sekiyama K; Sekigawa A; Fujita M; Waragai M; Sugama S; Iwamaru Y; Kitani H; Hashimoto M
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):91-6. PubMed ID: 20143170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?
    Marchetti B; Abbracchio MP
    Trends Pharmacol Sci; 2005 Oct; 26(10):517-25. PubMed ID: 16126283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma.
    Delgado M; Ganea D
    FASEB J; 2003 Oct; 17(13):1922-4. PubMed ID: 12923064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
    Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
    FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating interleukin-10 and interleukin-12 in Parkinson's disease.
    Rentzos M; Nikolaou C; Andreadou E; Paraskevas GP; Rombos A; Zoga M; Tsoutsou A; Boufidou F; Kapaki E; Vassilopoulos D
    Acta Neurol Scand; 2009 May; 119(5):332-7. PubMed ID: 18976327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapies in Parkinson's disease.
    Jankovic J; Poewe W
    Curr Opin Neurol; 2012 Aug; 25(4):433-47. PubMed ID: 22691758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.
    Hughes PM; Botham MS; Frentzel S; Mir A; Perry VH
    Glia; 2002 Mar; 37(4):314-27. PubMed ID: 11870871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347.
    Lund S; Porzgen P; Mortensen AL; Hasseldam H; Bozyczko-Coyne D; Morath S; Hartung T; Bianchi M; Ghezzi P; Bsibsi M; Dijkstra S; Leist M
    J Neurochem; 2005 Mar; 92(6):1439-51. PubMed ID: 15748162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
    Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
    Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinsonism in Caplan's syndrome.
    Rizzo G; Scaglione C; Lopane G; Pollini A; Tommasoni E; Martinelli P
    Neurol Sci; 2006 Apr; 27(1):67-9. PubMed ID: 16688603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic markers for Parkinson's disease.
    Chahine LM; Stern MB
    Curr Opin Neurol; 2011 Aug; 24(4):309-17. PubMed ID: 21464716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
    Strange PG
    Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.
    Zhang W; Qin L; Wang T; Wei SJ; Gao HM; Liu J; Wilson B; Liu B; Zhang W; Kim HC; Hong JS
    FASEB J; 2005 Mar; 19(3):395-7. PubMed ID: 15596482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern.
    Letiembre M; Liu Y; Walter S; Hao W; Pfander T; Wrede A; Schulz-Schaeffer W; Fassbender K
    Neurobiol Aging; 2009 May; 30(5):759-68. PubMed ID: 17905482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can Parkinson's disease pathology be propagated from one neuron to another?
    Dunning CJ; Reyes JF; Steiner JA; Brundin P
    Prog Neurobiol; 2012 May; 97(2):205-19. PubMed ID: 22115849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of age and gender on cytokine expression in a murine model of Parkinson's disease.
    Ciesielska A; Joniec I; Kurkowska-Jastrzebska I; Przybyłkowski A; Gromadzka G; Członkowska A; Członkowski A
    Neuroimmunomodulation; 2007; 14(5):255-65. PubMed ID: 18196934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dementia in Parkinson's disease.
    Aarsland D; Beyer MK; Kurz MW
    Curr Opin Neurol; 2008 Dec; 21(6):676-82. PubMed ID: 18989112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.